非美诺司他

CUDC-907 (订货以英文为准)

编号:C126527
CAS号:1339928-25-4
分子式:C23H24N8O4S
分子量:508.55
货号 品牌 包装 目录价 您的价格 库存 数量 购买
C126527-5mg 阿拉丁 5mg ¥751.90
C126527-1mg 阿拉丁 1mg ¥244.90
C126527-100mg 阿拉丁 100mg ¥8239.90
C126527-25mg 阿拉丁 25mg ¥2554.90
C126527-50mg 阿拉丁 50mg ¥4593.90
C126527-10mg 阿拉丁 10mg ¥1205.90
产品名称 CUDC-907
中文名称 非美诺司他
CAS号 1339928-25-4
分子式(M.F.) C23H24N8O4S
分子量(M.W.) 508.55
储存条件 -20°C储存
溶解性DMSO 102 mg/mL Water <1 mg/mL Ethanol <1 mg/mL
存贮条件储存温度-20°C
备注CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. Phase 1.
生化机理Description:IC50 Value: 1.7/5.0/1.8/2.8 nM (HDAC1/2/3/10); 19/54/39 nM (PI3Kα/β/δ) [1]CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.in vitro: CUDC-907 induced the accumulation of acetylated histone H3, tubulin, and p53, as well as p21 expression in a dose-dependent manner (Supplementary Figs. S2-S5). Similarly, we observed that CUDC-907 inhibited the PI3K pathway, as indicated by the dose-dependent decreases in phosphorylation of AKT and its downstream targets, 4EBP-1 and p70S6, in H460 cells. CUDC-907 induced caspase-3 and -7 activation in HCT-116 colon cancer cells in a dose-dependent manner [1].in vivo: oral administration of CUDC-907 inhibited growth of the Daudi cancer cell xenografts in a dose-dependent manner. Tumor stasis was observed at 100 mg/kg in this model without obvious toxicity. Furthermore, CUDC-907 caused tumor regression or stasis after intravenous (50 mg/kg) or oral administration (100 mg/kg) in a xenograft tumor model of SU-DHL4 diffuse large B-cell lymphoma (DLBCL) and caused tumor stasis in KRAS-mutant A549 NSCLC cell xenografts [1].Toxicity: oral administration of CUDC-907 inhibited growth of the Daudi cancer cell xenografts in a dose-dependent manner. Tumor stasis was observed at 100 mg/kg in this model without obvious toxicity [1].Clinical trial: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma. Phase 1
别名N-hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide;N-hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide
Reaxys-RN6467047
个人防护设备Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
RTECSEY8555800
WGK德国3
搜索质检报告(COA)
搜索MSDS
相关产品
CAS号:7704-98-5
¥ 419.00 T819979-100g
CAS号:7758-02-3
¥ 223.00 P816703-25g
CAS号:288-32-4
¥ 60.00 I811843-25g
CAS号:7791-20-0
¥ 899.00 N814991-5g
CAS号:71-41-0
¥ 115.00 P815993-500ml
CAS号:108-46-3
¥ 225.00 R817303-100g
CAS号:1499-10-1
¥ 556.00 D807000-250mg
CAS号:98-88-4
¥ 258.00 B802234-500g
CAS号:9002-92-0
¥ 520.00 767315-5g